Drug Profile
Eptinezumab - Lundbeck Seattle BioPharmaceuticals
Alternative Names: ALD-403; Eptinezumab-jjmr; Lu-AG09221; VYEPTILatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Alder Biopharmaceuticals
- Developer Lundbeck A/S; Lundbeck Seattle BioPharmaceuticals Inc.
- Class Analgesics; Antimigraines; Monoclonal antibodies
- Mechanism of Action Calcitonin gene-related peptide antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Migraine
- Phase III Cluster headache
Most Recent Events
- 05 Oct 2023 Lundbeck completes phase III ALLEVIATE trials in Cluster headache in United Kingdom, Sweden, Spain, Russia, Portugal, Norway, Greece, Germany, Georgia, France, Finland, Estonia, Denmark, Czech Republic, Belgium, Netherlands(NCT04688775; EudraCT2020-001969-37)
- 21 Aug 2023 Lundbeck completes a phase I trial in Migraine (Prevention, In children, In adolescents) in USA (IV) (NCT04537429)
- 29 Jun 2023 Lundbeck completes a phase III CHRONICLE trial in chronic cluster headache in Denmark, Italy, Finland, France, Germany, the Netherlands, Spain, united Kingdom and USA (NCT05064397)